Current approaches to gender dysforia management: an endocrinologist’s perspective

Cover Page

Cite item

Abstract

Understanding of people with impaired gender identity in society, academic and science world is constantly changing due to increased awareness, openness and availability of the information on transgender people and their life. It is known that the social and psychological state of transgenders depends at a  great extent on the quality of their medical care, including hormonal treatment. Unfortunately, until recently the awareness of this problem among many physicians (clinical psychologists, psychiatrists, endocrinologists, etc.) in the Russian Federation remained insufficient, and no unified standards of medical and psychological care for transgender people in Russia have been developed. As a  result, when referring to various specialists, people with impaired gender identity commonly do not receive adequate recommendations and proper comprehensive medical follow-up. An endocrinologist, who prescribes hormonal treatment and performs long-term (usually life-long) follow-up and monitoring of adverse events, is one of the key team members to provide medical care to transgender patients. The article presents current views on definitions, diagnostic criteria and principles of endocrine therapy for gender dysphoria and gender incongruence, as well as highlights medical risks, associated with hormonal treatment, and a monitoring plan for patients receiving corrective therapy.

About the authors

N. I. Volkova

The Rostov State Medical University

Email: fake@neicon.ru

Natalia I. Volkova – MD, PhD, Professor, Vice-Сhancellor on Scientific Research, Head of Department of Internal Diseases No. 3,

29, Nakhichevanskiy pereulok, Rostov-on-Don, 344022

Russian Federation

I. Yu. Davidenko

The Rostov State Medical University

Email: fake@neicon.ru

Ilya Yu. Davidenko – MD, PhD, Associate Professor, Department of Internal Diseases No. 3,

29, Nakhichevanskiy pereulok, Rostov-on-Don, 344022

Russian Federation

Yu. S. Degtyareva

The Rostov State Medical University

Author for correspondence.
Email: i.s.degtiareva@gmail.com

Yuliya S. Degtyareva – Residen, Department of Internal Diseases No. 3,

134 Evdokimova ul., Rostov-on-Don, 344068

Russian Federation

References

  1. Bullough VL. Transsexualism in history. Arch Sex Behav. 1975;4(5):561–71. doi: 10.1007/bf01542134.
  2. Benjamin H. The transsexual phenomenon. Trans N Y Acad Sci. 1967;29(4):428–30. doi: 10.1111/j.2164-0947.1967.tb02273.x.
  3. Meyerowitz J. How sex changed: A history of transsexuality in the United States. Cambridge, MA: Harvard University Press; 2002. doi: 10.1086/ahr/108.5.1479.
  4. The World Professional Association for Transgender Health (WPATH). Standards of Care [Internet]. WPATH; 2017. Available from: https://www.wpath.org/publications/soc/.
  5. World Health Organization (WHO). New International Classification of Diseases [Internet]. Available from: https://icd.who.int/.
  6. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine treatment of gender-dysphoric/ gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. Endocr Pract. 2017;23(12):1437. doi: 10.4158/1934-2403-23.12.1437.
  7. Wierckx K, Van Caenegem E, Pennings G, Elaut E, Dedecker D, Van de Peer F, Weyers S, De Sutter P, T'Sjoen G. Reproductive wish in transsexual men. Hum Reprod. 2012;27(2):483–7. doi: 10.1093/humrep/der406.
  8. Wierckx K, Stuyver I, Weyers S, Hamada A, Agarwal A, De Sutter P, T'Sjoen G. Sperm freezing in transsexual women. Arch Sex Behav. 2012;41(5): 1069–71. doi: 10.1007/s10508-012-0012-x.
  9. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6): 2536–59. doi: 10.1210/jc.2009-2354.
  10. T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of transgender medicine. Endocr Rev. 2019;40(1):97–117. doi: 10.1210/er.2018-00011.
  11. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93(1):19–25. doi: 10.1210/jc.2007-1809.
  12. Lapauw B, Taes Y, Simoens S, Van Caenegem E, Weyers S, Goemaere S, Toye K, Kaufman JM, T'Sjoen GG. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008;43(6):1016– 21. doi: 10.1016/j.bone.2008.09.001.
  13. Righini M, Perrier A, De Moerloose P, Bounameaux H. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost. 2008;6(7):1059–71. doi: 10.1111/j.1538-7836.2008.02981.x.
  14. Cunha FS, Domenice S, Câmara VL, Sircili MH, Gooren LJ, Mendonça BB, Costa EM. Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia. 2015;47(6): 680–4. doi: 10.1111/and.12317.
  15. Nota NM, Dekker MJHJ, Klaver M, Wiepjes CM, van Trotsenburg MA, Heijboer AC, den Heijer M. Prolactin levels during shortand long-term cross-sex hormone treatment: an observational study in transgender persons. Andrologia. 2017;49(6). doi: 10.1111/and.12666.
  16. Bunck MC, Debono M, Giltay EJ, Verheijen AT, Diamant M, Gooren LJ. Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. BMJ Case Rep. 2009;2009. pii: bcr02.2009.1589. doi: 10.1136/bcr.02.2009.1589.
  17. Gennari L, Khosla S, Bilezikian JP. Estrogen and fracture risk in men. J Bone Miner Res. 2008;23(10):1548–51. doi: 10.1359/jbmr.0810c.
  18. Van Caenegem E, Wierckx K, Taes Y, Schreiner T, Vandewalle S, Toye K, Lapauw B, Kaufman JM, T'Sjoen G. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI). Eur J Endocrinol. 2015;172(2):163–71. doi: 10.1530/EJE-14-0586.
  19. Van Caenegem E, Taes Y, Wierckx K, Vandewalle S, Toye K, Kaufman JM, Schreiner T, Haraldsen I, T'Sjoen G. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone. 2013;54(1):92–7. doi: 10.1016/j.bone.2013.01.039.
  20. Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer. 2011;11(6):417–9. doi: 10.1016/j.clbc.2011.06.006.
  21. Nikolic DV, Djordjevic ML, Granic M, Nikolic AT, Stanimirovic VV, Zdravkovic D, Jelic S. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J Surg Oncol. 2012;10:280. doi: 10.1186/1477-7819-10-280.
  22. Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA; UK Clinical Cytogenetics Group. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol. 2008;9(3):239–46. doi: 10.1016/S1470-2045(08)70033-0.
  23. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with crosssex hormones. Eur J Endocrinol. 2008;159(3): 197–202. doi: 10.1530/EJE-08-0289.
  24. Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J. 2013;7(7–8):E544–6. doi: 10.5489/cuaj.175.
  25. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185–91. doi: 10.7326/0003-4819-149-3-200808050-00008.

Copyright (c) 2019 Volkova N.I., Davidenko I.Y., Degtyareva Y.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies